In a filing with the US Securities and Exchange Commission (SEC), Canadian biotech Zymeworks (NYSE: ZYME) has revealed the sudden replacement of its chief financial officer.
The oncology specialist, which recently completed a private $50 million share placement, provided no reason for the removal of Christopher Astle from the position of CFO, and senior vice president.
However, multiple law firms, including Levi & Korsinsky and Kirby McInerney, have announced they intend to investigate possible unlawful business practices, including a possible violation of federal securities law.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze